Published in final edited form as:

Trends Cell Biol. 2016 May ; 26(5): 352–366. doi:10.1016/j.tcb.2015.12.006.

Stress-induced EGFR trafficking: mechanisms, functions, and therapeutic implications

Xiaojun Tan¹, Paul F. Lambert², Alan C. Rapraeger³, and Richard A. Anderson^{*,1}

¹Program in Molecular and Cellular Pharmacology, University of Wisconsin-Madison School of Medicine and Public Health, 1300 University Avenue, Madison, WI 53706, USA

²Department of Oncology, ² McArdle Laboratory for Cancer Research, University of Wisconsin-Madison School of Medicine and Public Health, 1300 University Avenue, Madison, WI 53706, USA

³Department of Human Oncology, University of Wisconsin-Madison School of Medicine and Public Health, 1300 University Avenue, Madison, WI 53706, USA

Abstract

Epidermal growth factor receptor (EGFR) has fundamental roles in normal physiology and in cancer, making it a rational target for cancer therapy. Surprisingly, however, inhibitors that target canonical, ligand-stimulated EGFR signaling have proven to be largely ineffective in treating many EGFR-dependent cancers. Recent evidence indicates that both intrinsic and therapy-induced cellular stress triggers robust, non-canonical pathways of ligand-independent EGFR trafficking and signaling, which provides cancer cells with a survival advantage and resistance to therapeutics. Here we review the mechanistic regulation of non-canonical EGFR trafficking and signaling, the pathological and therapeutic stresses that activate it, and discuss the implications of this pathway in clinical treatment of EGFR-overexpressing cancers.

Keywords

EGFR; cellular stress; ligand-independent trafficking; autophagy; cancer therapy

EGFR trafficking in cancer signaling and therapies

Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase with fundamental roles in development and normal physiology of epithelial cells [1], including stimulating cell proliferation, differentiation, and motility. Overexpression and/or hyperactivation of EGFR is a predictor of poor prognosis in many cancers, where it drives tumor initiation and progression [2]. Full activation of EGFR, as well as termination of its signaling, depends on

*To whom correspondence should be addressed: raanders@wisc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ligand-stimulated endocytosis and intracellular trafficking (Figure 1). It has been proposed that dysregulation of this sorting process contributes to oncogenesis in many carcinomas.

Here, we briefly summarize ligand-stimulated EGFR trafficking pathways; for details, readers are referred to other reviews [3–6]. Upon ligand binding, EGFR is autophosphorylated and initiates signaling at the plasma membrane. The phosphotyrosine residues generated by this activation provide docking sites for downstream effectors, such as the E3 ubiquitin ligase CBL, the phosphoinositide 3-kinase (PI3K) complex, Src kinase, and growth factor receptor-bound protein 2 (GRB2) [7]. Activated EGFR is rapidly internalized to endosomes by clathrin-dependent and -independent routes, where it continues to signal until recycled to the plasma membrane in the case of TGF α binding, or is extinguished in lysosomes if occupied by EGF [8]. Lysosomal destruction of activated EGFR requires receptor ubiquitination, which starts at the plasma membrane and continues in endosomes [6], causing it to be recognized by the **endosomal sorting complex required for transport** (ESCRT, see Glossary) machineries that drive its sorting into intraluminal vesicles (ILVs) at **multivesicular endosomes** (MVEs) and degradation following MVE fusion with lysosomes [9, 10]. In addition to these recycling and lysosomal sorting pathways, recent studies have also reported ligand-stimulated EGFR trafficking to mitochondria [11–13] and nuclei [14–16] (Figure 1). In some situations, nuclear or mitochondrial localization is also induced by cellular stressors, as discussed further below.

Due to its frequent overexpression and hyperactivation, EGFR has been a therapeutic target for many epithelial cancers. Three small molecule tyrosine kinase inhibitors (TKIs), Erlotinib, Gefitinib and Lapatinib, and two EGFR-specific antibodies, Cetuximab and Panitumumab, have been shown to efficiently suppress ligand-stimulated EGFR kinase activity in clinical studies [2]. However, these drugs have little or no effect in most solid tumors with the exception of non-small cell lung cancers (NSCLC) carrying activating mutations in EGFR, which initially respond to the TKIs but eventually develop resistance [2, 17–21]. Despite the possible existence of additional oncogenic factors in wild-type EGFR expressing cancers, the innate resistance to canonical EGFR signaling inhibitors suggests that previously unappreciated non-canonical EGFR signaling pathways, including ligand-independent and potentially tyrosine kinase-independent mechanisms, are likely to play a role (Box 1).

Box 1

Kinase-independent EGFR functions

It has been known for years that there are kinase-independent roles for EGFR in normal physiology. Mice with kinase-dead EGFR survive better than EGFR-knockout mice. The EGFR-knockout mice die before or after birth with severe developmental defects, depending on the genetic background [107–109]. However, mice with kinase dead EGFR can survive well with obvious defects only in the eyes and skin [110]. It is equally possible that kinase-independent EGFR functions can be essential for cancer cells. In fact, while kinase-activating mutations of EGFR are commonly found in NSCLCs, kinase dead mutations are also found [111], though the role for kinase-dead EGFR in these cases

are not clear. However, more recent work may now help us understand why these kinase dead EGFR mutants could still play important roles in cancers.

Over the past 20 years, a number of studies have reported kinase-independent functions of EGFR in cell survival [22, 112–114]. Expressing of either wild type or the K721R kinase dead mutant of EGFR promotes cell survival in the absence of interleukin 3 (IL3) in 32D murine hematopoietic cells that normally depend on IL3 for growth and survival [114]. Interestingly, another kinase dead mutant D813A does not provide similar survival advantage in the same cells. Similarly, K721M mutant can still stimulate the expression of c-fos, a proto-oncogene [115]. However, D813A but not K721 mutants of EGFR is able to stimulate DNA synthesis [113]. These results suggest that specific conformations but not the kinase activity of EGFR is important for certain cell survival functions.

At the plasma membrane, EGFR associates with and stabilizes the sodium/glucose co-transporter 1 (SGLT1), which is independent of EGFR kinase activity [112]. As such EGFR facilitates cancer cell survival by maintaining cellular glucose levels even without its tyrosine kinase activity. In fact, SGLT1 expression levels in oral squamous cell carcinoma cell lines and patient tumors are significantly correlated with EGFR levels, and their expression is inversely related to tumor differentiation [116].

With the recently identified role in autophagy, now EGFR is known to have at least four distinct kinase-independent functions, including selective protein expression, DNA synthesis, intracellular glucose level maintenance, as well as autophagy. There are surely more kinase-independent EGFR functions to be discovered in future studies, but the current data have already transformed our understanding of EGFR in cancer biology, which should now be seriously taken into account when considering EGFR targeting in clinical therapies.

Recent advances have shown that many intrinsic and iatrogenic cellular stresses induce ligand-independent EGFR transactivation, internalization, and intracellular trafficking (Figure 1), which is associated with resistance to EGFR targeting therapies. In addition, kinase-independent EGFR functions have been reported, including, among others, a role for the endosomal-accumulated, inactive EGFR in the induction of autophagy [22]. While the other kinase-independent functions for EGFR (Box 1) are less well understood, its role in autophagy initiation is clearer and more targetable for cancer treatments. Although the core autophagy machinery is evolutionarily conserved in all eukaryotes, mammalian cells have evolved more complex regulatory mechanisms for the control of autophagy in order to maintain cellular homeostasis in response to constantly changing environments and physiological conditions. Misregulation of autophagy is observed in various diseases, including cancers, neurodegenerative diseases, and aging. High autophagy levels, assessed by punctate LC3B staining, are frequently associated with solid tumors and correlate with tumor malignancy, metastasis, and poor outcome [23]. Tumors with hypoxic stress intrinsically upregulate transcriptional EGFR expression through HIF2 α , providing an explanation for non-mutational EGFR overexpression in cancers [24]. Given the overexpression of EGFR in many epithelial cancers and the capability of EGFR to respond to many cellular stressors, it is not surprising that cancer cells would make use of readily

available EGFR molecules to survive stressed conditions by activating pathways such as autophagy. Thus, targeting autophagy in combination with canonical EGFR-targeting therapies is likely a promising approach for the treatment of solid tumors with wild type EGFR overexpression.

Ligand-independent EGFR functions is emerging as resistant mechanisms for canonical therapies of EGFR driven cancers. Below we review the current understanding of ligand-independent EGFR trafficking and functions stimulated by various cellular stresses or stress-inducers, and discuss their implications for new approaches to cancer therapy.

Endosomal-accumulated inactive EGFR in autophagy initiation

Growth factor signaling directs the utilization of nutrients to maintain cell survival and growth [25]. Autophagy is a highly conserved self-eating process that maintains cellular homeostasis and functions as a survival mechanism under stressed conditions (for recent reviews, see refs [26, 27]). In nutrient-rich conditions with sufficient growth factors, EGFR activation stimulates cell survival, proliferation, and migration [28]. It also suppresses autophagy by activating the Akt-mTORC1 pathway or by directly phosphorylating and inhibiting Beclin 1 (Atg6 in yeast), a core subunit of the VPS34 autophagy-initiating complex [29]. In contrast, whereas activated EGFR suppresses autophagy, recent studies have revealed a role for inactive EGFR in autophagy initiation (Figure 2), which can be stimulated by serum starvation or EGFR TKIs [22].

Endosomal EGFR accumulation during serum starvation is due to a strong interaction between inactive EGFR and LAPT4B (lysosomal-associated protein transmembrane 4 beta), a four-transmembrane protein that is localized to a fraction of early and late endosomes [30] and is overexpressed in many cancers [31, 32]. Surprisingly, inactive EGFR and LAPT4B stabilize each other at these non-degradative endosomes. This intracellular arrest phenotype appears similar to that observed after UV irradiation or cisplatin treatment [33]. However, serum starvation specifically increases the endosomal pool of EGFR without affecting cell surface EGFR levels [22], whereas UV irradiation or cisplatin treatment triggers acute EGFR internalization [33]. Of note, the K721A kinase-dead EGFR mutant maintains a strong LAPT4B interaction and still accumulates in LAPT4B-positive endosomes. It is likely that during basal ligand-independent EGFR trafficking and turnover, a fraction of inactive EGFR is recognized by LAPT4B and is then sequestered at endosomes.

At the endosome, inactive EGFR regulates the Beclin1 autophagy-initiating complex (Figure 2). The Beclin1-VPS34 (class III PI3K) complex plays an essential role in autophagy initiation by generating phosphatidylinositol 3-phosphate (PI3P) at the ER where PI3P effectors are recruited for phagophore assembly [34–37]. The **Run domain Beclin-1 interacting and cysteine-rich containing protein** (Rubicon) is an autophagy inhibitor, and, when associated with the Beclin 1 complex, it inhibits PI3P generation [38]. With the help of LAPT4B and Sec5 exocyst subcomplex at endosomes, the inactive EGFR complex interacts with Rubicon and promotes its disassociation from Beclin 1, resulting in Beclin 1 activation and autophagy initiation [22]. In support of this mechanism, the exocyst complex

has been recently reported to regulate autophagy initiation in both mammals and plants [39, 40]. Interestingly, this receptor-mediated autophagy pathway appears specific to EGFR, as loss of other receptors, such as c-Met, PDGFR β , or FGFR2, does not cause autophagy defects.

Most solid tumors have innate resistance to EGFR TKIs and receive no clinical benefits from these inhibitors [2]. Recently, many groups have found that EGFR TKIs induce cytoprotective autophagy in cancer cells as an innate TKI-resistance mechanism [17, 41–49]. Since EGFR activation suppresses autophagy by multiple mechanisms, the TKI-stimulated autophagy was thought to result from a loss-of-function for EGFR kinase signaling. However, a gain-of-function for EGFR in autophagy initiation upon TKI (erlotinib or gefitinib) treatment has been discovered (Figure 2). TKIs also trigger EGFR accumulation at endosomes and enhance its association with the exocyst complex and Rubicon, inducing Rubicon disassociation from Beclin 1 and activating autophagy initiation [22]. Therefore, the EGFR TKIs mimic the function of LAPTM4B in stabilizing EGFR at endosomes and facilitating EGFR recruitment of downstream effectors to modulate autophagy.

It is likely that the role for EGFR in autophagy initiation is not only induced by serum starvation and TKI treatments, but it may also act downstream of other stresses (Figure 2). Not only LAPTM4B and TKIs arrest EGFR at non-degradative endosomes, other stress inducers, such as ultraviolet (UV) irradiation, cisplatin treatment, hypoxia, oxidative stress, protein kinase A (PKA) inhibition, etc., also stimulate EGFR internalization and endosomal arrest, although the underlying mechanisms are stress-dependent. It appears that most stressors stimulate either p38MAPK- and clathrin-mediated or Src- and caveolin-mediated EGFR internalization (Table 1). Interestingly, EGFR TKIs are known to induce both oxidative stress – which activates Src – and p38 MAPK activation [46, 54], suggesting that both pathways might be involved in EGFR internalization and intracellular arrest upon TKI treatment [22]. Of note, although two distinct mechanisms are used for the internalization of EGFR, almost all stimuli including serum starvation can induce oxidative stress [55] and endosomal arrest of EGFR (Figure 2), putting them at the forefront of many stress response pathways. It is therefore important to know, in each stressed condition, whether the endosomal EGFR gains a function in autophagy initiation.

p38MAPK-mediated EGFR internalization and endosomal arrest

A number of cellular stress inducers, including UV irradiation, the antibiotic anisomycin, cisplatin, and tumor necrosis factor alpha (TNF- α), have all been found to induce ligand-independent EGFR internalization (Table 1). A commonality is that they all trigger activation of **p38 mitogen-activated protein kinases** (p38MAPK) that is required for EGFR internalization in these conditions. Among them, the best-characterized stimulus is UV irradiation.

UV irradiation induces rapid, ligand-independent, and clathrin-mediated internalization of EGFR, with kinetics comparable to those induced by high concentrations of EGF [33, 53]. Interestingly, other receptors including c-Met, insulin receptor, and transferrin receptor are not affected by UV irradiation [33, 53]. While EGF-stimulated EGFR internalization is

tyrosine kinase-dependent and requires autophosphorylation of multiple tyrosines, UV-stimulated internalization is tyrosine kinase-independent [50]. Instead, it requires phosphorylation of serine and threonine residues in the EGFR cytoplasmic carboxy-terminal tail (C-tail) [51] as well as continual activation of p38MAPK by UV irradiation [52, 53]. The antibiotic, anisomycin, like UV, also induces p38MAPK-mediated EGFR internalization that is independent of EGFR tyrosine kinase activity, tyrosine phosphorylation, and ubiquitination [52]. EGFR is phosphorylated at Ser1039 and Thr1041, as well as at other Ser/Thr residues downstream of p38MAPK upon anisomycin treatment, and these residues are also phosphorylated at very low levels in response to EGF [56, 57]. How the differential phosphorylation patterns correlate with the distinct intracellular trafficking routes upon stress or EGF stimulation is an important future direction for study in EGFR trafficking.

Unlike EGF that stimulates EGFR degradation, UV induces stable EGFR accumulation or arrest in endosomal compartments [50]. Although EGFR degradation is ultimately observed after long-term UV exposure, this may reflect nonspecific cleavage by caspases triggered by the onset of apoptosis rather than sorting to lysosomes [58]. Surprisingly, although the overall response of EGFR to anisomycin and UV appears similar, anisomycin triggers fast EGFR degradation, though apparently through ubiquitination- and lysosome-independent mechanisms as well [52]. Inflammatory cytokines, such as TNF- α , induce transient p38MAPK activation and EGFR phosphorylation and internalization, followed by rapid recycling once p38MAPK is inactivated [53].

The UV-induced endosomal accumulation of EGFR is due not to persistent internalization and recycling, but rather to p38MAPK-mediated endosomal arrest of EGFR [33]. Arrested EGFR is observed in a population of lysobisphosphatidic acid (LBPA)-positive MVEs that are distinct from the EGF-induced pool of MVEs and do not fuse with lysosomes [33]. UV induces ubiquitination-independent, ALG-2-interacting protein X (ALIX)- and ESCRT-dependent sorting of EGFR onto ILVs at these non-degradative MVEs [33, 50]. Interestingly, the intraluminally sorted EGFR can be recycled back to the plasma membrane upon inhibition of p38MAPK, suggesting **back-fusion** of the ILVs with the limiting membrane of MVEs [33]. In support of this, the UV-induced EGFR signaling requires ALIX [33], suggesting that the dynamic sub-endosomal EGFR trafficking plays a key role in regulating receptor signaling.

The chemotherapeutic reagent cisplatin also triggers p38MAPK-mediated EGFR phosphorylation, internalization, and endosomal arrest without EGFR ubiquitination or degradation [33, 53]. Interestingly, both UV and cisplatin stimulate cytoprotective autophagy, which is a resistance mechanism for UV- or cisplatin-induced cell death [59–66]. This raises the important question: does endosomally accumulated EGFR mediate UV- or cisplatin-induced autophagy? This question is addressed here and in ref [22].

Src- and caveolin-mediated EGFR internalization and endosomal accumulation

Hypoxia, as well as nutrient deprivation, is a common condition in solid tumors, and it contributes to metabolic rewiring of cancer cells, angiogenesis, and metastasis. EGFR also

responds to hypoxia to provide a cell survival advantage (Table 1). Hypoxia not only transcriptionally upregulates EGFR expression [24], it also transactivates EGFR and triggers its internalization and late endosomal accumulation [67]. Hypoxia activates Src [68] and potentially stimulates caveolin-mediated internalization of EGFR, as discussed below. Hypoxia dramatically stimulates EGFR interaction at late endosomes with argonaute 2 (AGO2), a membrane-associated protein involved in miRNA (miRNA) maturation [67]. Hypoxia-transactivated EGFR phosphorylates AGO2, resulting in inhibited maturation of select tumor suppressor miRNAs, which in turn promotes EGFR-mediated cancer cell survival and invasiveness [67]. Interestingly, oxidative stress also stimulates the EGFR-AGO2 interaction, albeit not as well as hypoxia, suggesting that the EGFR-mediated processing of tumor suppressor miRNA could be a general stress response. Hypoxia is also a potent stimulator of autophagy through multiple mechanisms [69], but a role for the late endosomally accumulated EGFR in hypoxia-induced autophagy is not defined.

Oxidative stress is a normal physiological condition, but it also has roles in numerous diseases, including cancer. Oxidative stress induced by H₂O₂ (or glucose oxidase that generates H₂O₂) stimulates EGFR activation without ubiquitination or degradation of EGFR (Table 1), possibly due to little phosphorylation at Tyr1045, the docking site for the E3 ubiquitin ligase CBL that ubiquitinates EGFR [70]. Importantly, H₂O₂ induces conformational changes in EGFR that differ from those induced by EGF. H₂O₂ causes EGFR phosphorylation but not dimerization, and the phosphorylation is resistant to treatment by the EGFR TKI tyrphostin (AG1478) [71], which might be partially due to H₂O₂-mediated oxidation and inactivation of tyrosine phosphatases that negatively regulate EGFR phosphorylation [72, 73] or due to EGFR phosphorylation by other kinases than EGFR itself [74]. Similar to other stressors discussed above, H₂O₂ also causes EGFR internalization and perinuclear arrest [75]. However, H₂O₂-stimulated EGFR internalization is caveolin-dependent and likely promoted by Src kinase activity, as discussed below [75]. Oxidative stress is emerging as the converging point for many cellular stresses that stimulate autophagy [55]; so is EGFR as discussed throughout this review (Figure 2).

An additional way to trigger perinuclear arrest of EGFR without causing its lysosomal degradation is by inhibiting PKA signaling (Table 1). Initial studies have found that inhibition of phosphatidic acid (PA) phosphohydrolases (PAPs) causes ligand- and tyrosine kinase-independent internalization of EGFR with no evidence for tyrosine phosphorylation, ubiquitination, or degradation of EGFR [76, 77]. PA accumulation inhibits PKA signaling, resulting in EGFR internalization through both clathrin-dependent and -independent routes [76]. Though the functional relevance for PKA-inhibition-induced EGFR endosomal accumulation is not clear, it might participate in autophagy initiation (Figure 2). Protein kinase A (PKA) is an established negative regulator of autophagy that functions upstream of the ULK1 (atg1 in yeast) complex independently of the mechanistic target of rapamycin complex 1 (mTORC1) [78], and more extensive feedback regulation between PKA signaling and autophagy has been recently revealed [79, 80].

Caveolin-mediated EGFR internalization and nuclear translocation

Cetuximab binds the EGFR extracellular domain, blocks ligand binding, and inhibits EGFR activation. Cetuximab also induces strong internalization of EGFR, potentially through caveolin-mediated mechanisms (Table 1) [81], but the downstream trafficking events have been uncharacterized to date. However, it has been established that cetuximab can stimulate EGFR trafficking to the ER and the nucleus [82]. Interestingly, erlotinib and gefitinib, but not lapatinib, promote cetuximab-induced nuclear translocation of EGFR, suggesting that EGFR kinase activity is not required, but a unique receptor conformation is crucial because erlotinib and gefitinib keep EGFR in a different conformation as does lapatinib. The nuclear EGFR trafficking is associated with cancer resistance to cetuximab therapy, but there are also many other resistance mechanisms [83]. Recently, cetuximab has been reported to stimulate cytoprotective autophagy in a number of cancer cell lines [84]. The underlying mechanisms for autophagy induction has been attributed to cetuximab-stimulated down-regulation of hypoxia-inducible factor-1 (HIF-1) as well as Bcl-2, which in turn releases Beclin 1 from Bcl-2 suppression [85]. However, whether cetuximab triggers endosomal arrest of EGFR or whether the cetuximab-bound, internalized EGFR itself has a gain-of-function in autophagy has not been explored.

A major therapeutic approach for treating localized tumors is ionizing radiation, a treatment for which EGFR is known to provide cellular resistance (Table 1). EGFR expression levels are upregulated by ionizing irradiation [86]. Radiation also stabilizes and activates Src kinase that in turn phosphorylates caveolin-1 and EGFR, resulting in caveolin-mediated EGFR internalization [81]. In addition, radiation triggers PKC ϵ -mediated EGFR phosphorylation at Thr654 [87], which blocks CBL-mediated EGFR ubiquitination and lysosomal degradation and promotes EGFR nuclear transport [88]. The nuclear EGFR might contribute to enhanced DNA repair [81], and kinase inhibition of Src causes a block of EGFR nuclear transport upon radiation [14]. H₂O₂-induced oxidative stress as well as UV irradiation also stimulates rapidly nuclear translocation of EGFR in human keratinocytes [89], which may control resistance to DNA damage. Overexpression, transactivation, and nuclear localization of EGFR are all associated with radio-resistance and poor therapeutic outcome; thus, EGFR targeting has been a strategy to re-sensitize tumors to radiotherapy [90]. However, resistance to EGFR inhibitors is observed when used in combination with radiation, for which autophagy is emerging as a resistance mechanism. Although it is not resolved if the inactive EGFR plays a role in radiation-induced autophagy, it is known that autophagy is strongly upregulated by radiation in radio-resistant, but not radio-sensitive cells, and that autophagy inhibition can re-sensitive resistant cells to radiation [91, 92].

Stress-induced mitochondrial translocation of EGFR

The mitochondrion is positioned at the center of cellular pathways controlling metabolism, survival, and death, where it modulates not only apoptosis but also autophagy. EGFR has been shown to translocate to mitochondria in multiple conditions, and it potentially regulates mitochondrial pathways in cell survival (Figure 1). Even without mitochondrial localization, both EGFR and **EGFRvIII** (the most common deletion mutant of EGFR in cancers) have been shown to interact with the p53-upregulated modulator of apoptosis (PUMA) to inhibit

PUMA translocation to mitochondria and PUMA-mediated apoptosis [93]. It is not defined which part of EGFR binds PUMA, but this function does not require EGFR kinase activity.

Both EGF and some stress stimuli can induce EGFR translocation to mitochondria (Figure 1). Upon EGF stimulation, mitochondrial EGFR phosphorylates Cytochrome c oxidase subunit II (COXII), resulting in decreased Cox activity and cellular ATP levels, which prevents apoptosis [12]. EGF also stimulates a role for mitochondrial EGFR in the fission and redistribution of mitochondria, which is associated with enhanced cancer cell motility [94]. Alternatively, activation of cell surface EGFR has been proposed to stimulate *de novo* synthesis of palmitate that in turn activates mitochondrial EGFR to promote mitochondrial fusion and cancer cell survival [95]. Mitochondrial localization of EGFR can also be independent of EGFR endocytosis, suggesting direct EGFR delivery to mitochondria upon synthesis [13].

EGFR also translocates to mitochondria and provides drug resistance in stressed conditions triggered by apoptotic inducers staurosporine, anisomycin, or gefitinib [96]. Cetuximab treatment does not induce mitochondrial translocation of wild-type EGFR but does induce translocation of EGFRvIII and increased mitochondrial activity without affecting the kinase activity of EGFRvIII [97], suggesting potential cetuximab resistance mediated by mitochondrial EGFRvIII. How this leads to drug resistance is not yet defined, but it could involve changes of mitochondrial activity or autophagy (Figure 2), the latter of which antagonizes apoptosis and is induced by gefitinib. Thus, EGFR potentially contributes to autophagy at ER-mitochondria and/or ER-endosome contact sites (Box 2). Consistently, the autophagy inducer rapamycin triggers EGFR translocation to mitochondria, which is inhibited by the autophagy inhibitor 3-MA or by knockdown of Beclin 1 [11]. Interestingly, cells with more mitochondrial EGFR are more vulnerable to EGF treatment or EGFR knockdown [11], suggesting a dependence on mitochondrial EGFR-mediated survival functions.

Box 2

A potential role for inactive EGFR at the ER-mitochondria or ER-endosome contact sites for autophagy initiation

Autophagy initiation involves complex membrane trafficking events that deliver membrane vesicles to the phagophore nucleation sites. It is generally agreed that starvation-induced autophagy initiates at ER, but the membrane from not only ER but also ER-Golgi intermediate compartments (ERGIC), Golgi, early and recycling endosomes, plasma membrane, and mitochondria all contributes to phagophore expansion [26, 27]. A role for ER-mitochondria contact sites in phagophore formation has been recently established [117]. It is plausible that stress-induced mitochondrial translocation of EGFR [11] plays a role in autophagy initiation in these conditions.

Remarkably, the endosomal localized inactive EGFR also has an essential role in autophagy initiation by releasing Rubicon-free Beclin 1 [22], the latter of which is expected to mediate autophagy initiation at ER in close proximity. The MVEs have well established roles in fusion with autophagosomes as pre-degradative compartments [118].

However, given the constant contacts between ER and MVEs [119–122], it tends to postulate that the ER-MVE contact sites might provide a platform for the endosomal inactive EGFR to effectively regulate the Beclin 1 complex for autophagy initiation. It will be important to explore whether the endosomes, where EGFR accumulates upon serum starvation, TKI treatment, UV irradiation, or cisplatin treatment, have contacts with ER and if yes whether these contacts are involved in autophagy initiation. In fact, there are endosome-ER contact sites specified by an interaction between the ER-localized PTP1B and endosomal EGFR, where PTP1B de-phosphorylates and inactivates EGFR [119]. It is yet to be determined whether the PTP1B-EGFR mediated contact sites play a role in EGFR-mediated autophagy initiation.

Therapeutic implications for stress-induced EGFR functions

Since EGFR and autophagy are both at the converging point responding to intrinsic and iatrogenic stress, it would be beneficial to combine autophagy inhibition with other therapeutic approaches for EGFR-overexpressing cancers (Figure 3). In line with this, both EGFR-overexpressing cell lines and xenografts have been found to depend on autophagy for growth and survival, and autophagy-inhibition sensitizes them to irradiation [98, 99]. However, given that autophagy is also fundamental in normal physiology, general autophagy inhibition might cause serious problems, such as neurodegeneration and immunosuppression. Therefore, developing a list of autophagy inhibitors that specifically target certain types of cancers (*e.g.*, EGFR-overexpressing cancers) is critical for patients. To resolve this problem, detailed mechanisms for the inactive EGFR-mediated autophagy should be further dissected and more specific targets identified. As in cells with higher EGFR, more autophagic activity might depend on the EGFR-mediated autophagy pathway; specific inhibition of this pathway in combination with canonical EGFR targeting approaches as well as general chemo- and radiotherapies would induce more powerful and selective killing of EGFR-overexpressing cancer cells.

In addition, new EGFR TKIs that target not only ligand-activated EGFR but also transactivated EGFR are needed (Figure 3). Although autophagy is mediated by kinase-independent EGFR functions, many clinically used treatments transactivate a fraction of EGFR that signals at the plasma membrane, endosomes, mitochondria, and/or nuclei, and the transactivated EGFR can be resistant to currently available TKIs. For example, oxidative stress, which is induced by many therapeutic approaches, may not only stimulate kinase-independent role for EGFR in autophagy, but also transactivate a fraction of EGFR by inducing unique conformational changes, which cannot be targeted by canonical EGFR TKI tyrphostin [71]. Further investigation of the unique EGFR conformations and discovery of new TKIs that effectively inhibit transactivated EGFR might be key to overcoming current clinical resistance.

Moreover, stressed-induced EGFR trafficking could be additionally targeted to antagonize therapeutic resistance. Since stress-induced EGFR functions are tightly bound to EGFR internalization and intracellular trafficking – and certain functions are associated with specific subcellular localizations, such as non-degradative endosomes, mitochondria, and

nuclei – therapeutic interventions that block these trafficking events or alternatively direct internalized EGFR for lysosomal degradation can be considered as a combined approach with canonical therapies (Figure 3).

Furthermore, the PKA inhibition approach can be explored for treatment of EGFR overexpressing cancers (Figure 3). The clinically available PAP inhibitors, propranolol and desipramine, are known to cause PA accumulation and PKA inhibition, resulting in EGFR internalization. Although this mimics EGFR trafficking induced by other cellular stresses, PKA inhibition shows tumor suppression activities in EGFR-driven cancer cells [100]. Thus, PKA inhibition reagents could be further explored in combination with other therapeutic approaches such as EGFR inhibition, radiation, and autophagy suppression.

Finally, strategies to enhance precise delivery of EGFR targeting therapies can be employed (Figure 3). For example, as hypoxia is a common feature of solid tumors that upregulate and transactivate EGFR, the recently designed hypoxia-activated EGFR inhibitor [101] could be a promising approach to effectively and specifically inhibit EGFR signaling in hypoxic solid tumors.

Concluding remarks

Ligand-stimulated EGFR signaling plays pivotal roles in many cancers, and it is a crucial target for cancer treatments. However, due to the limited clinical response and frequent patient resistance to current therapies targeting ligand-stimulated EGFR signaling, new strategies to overcome resistance have become a major focus for this field. It is now clear that both intrinsic and iatrogenic cellular stressors can trigger ligand-independent EGFR internalization through p38 MAPK- and clathrin-mediated or Src- and caveolin-mediated mechanisms. The internalized EGFR primarily traffics to endosomes, mitochondria, ER, and nuclei, where ligand-independent EGFR functions are mediated by tyrosine kinase-dependent (transactivation) and -independent pathways, both of which can evade canonical EGFR TKI treatments and can potentially be manipulated to overcome resistance. We have discussed the ligand-independent EGFR trafficking and functions in response to many cellular stress stimuli, with an emphasis on a kinase-independent role for EGFR in autophagy that is potentially stimulated in most stressed conditions. We have also suggested potential therapeutic strategies to be combined with canonical treatments for EGFR overexpressing cancers, including co-targeting EGFR and autophagy, as both of them are at the converging point responding to intrinsic and iatrogenic stresses. Clearly, many questions remain to be addressed (see Outstanding questions). We hope this work will stimulate more extensive research on the mechanistic regulation of non-canonical EGFR trafficking and functions and the development of more effective EGFR targeting therapies.

Outstanding questions

Why does EGFR respond to so many stressors? What makes EGFR unique compared to other receptors that do not respond? Are there other receptors mediating stress responses similarly to EGFR?

How is EGFR post-translationally modified (phosphorylation and ubiquitination) upon different cellular stresses and how does different modification specify EGFR internalization and trafficking routes?

How do different stressors induce endosomal EGFR accumulation/arrest? Does stress-induced endosomal EGFR arrest always involve ubiquitination-independent EGFR intraluminal sorting and back-fusion recycling? How is this sub-endosomal trafficking of EGFR regulated, and how could it be inhibited to block transactivated EGFR signaling and autophagy?

Do all of those stress stimuli trigger the role for EGFR in autophagy? Does EGFR transactivated by all stress stimuli adopt a similar aberrant conformation as induced by oxidative stress and how could it be pharmacologically inhibited? Can the aberrantly activated EGFR stimulate autophagy?

Is there a way to pharmacologically induce a transition of those EGFR-positive non-degradative MVEs into degradative ones or to simply stimulate their fusion with lysosomes? Is there a way to promote lysosomal targeting of the fraction of EGFR that would otherwise translocates to mitochondria or nuclei?

Acknowledgments

We thank Kadina Johnston for comments on this manuscript. This work is supported by National Institute of Health grants CA104708 and GM057549 to R.A.A., CA163662 and CA139872 to A.C.R., CA022443-38 to P.F.L. and a Howard Hughes Medical Institute International Student Research Fellowship [grant number 59107631] to X.T.

Glossary

Endosomal Sorting Complex Required for Transport (ESCRT)

a series of multi-subunit complexes that mediate the recognition and intraluminal sorting of transmembrane receptor cargos

Multivesicular Endosome (MVE)

a subset of endosomes with multiple intraluminal vesicles (ILVs)

Run domain Beclin-1 interacting and cysteine-rich containing protein (Rubicon)

an inhibitor of autophagy primarily found at late endosomes/lysosomes that associates with and suppresses the activity of the Beclin 1-VPS34 complex

p38 mitogen-activated protein kinases (p38MAPK)

a class of protein kinases participating in a signaling cascade controlling cellular responses to cytokines and stress

Back-fusion

fusion of intraluminal vesicles with the limiting membrane of an MVE

Oxidative stress

cellular exposure to reactive oxygen species (ROS) that are highly reactive oxidizing molecules produced either endogenously or exogenously and can attack and damage biomolecules

EGFRvIII

the type III EGFR mutation that lacks part of the extracellular ligand-binding domain and is constitutively active. It is the most common deletion mutation of EGFR

References

1. Lemmon MA, Schlessinger J. Cell Signaling by Receptor Tyrosine Kinases. *Cell*. 2010; 141(7): 1117–1134. [PubMed: 20602996]
2. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. *Semin Oncol*. 2006; 33(4):369–85. [PubMed: 16890793]
3. Jones S, Rappoport JZ. Interdependent epidermal growth factor receptor signalling and trafficking. *The International Journal of Biochemistry & Cell Biology*. 2014; 51(0):23–28. [PubMed: 24681003]
4. Sorkin A, von Zastrow M. Endocytosis and signalling: intertwining molecular networks. *Nat Rev Mol Cell Biol*. 2009; 10(9):609–22. [PubMed: 19696798]
5. Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. *Exp Cell Res*. 2003; 284(1):78–88. [PubMed: 12648467]
6. Eden ER, et al. The role of EGF receptor ubiquitination in regulating its intracellular traffic. *Traffic*. 2012; 13(2):329–37. [PubMed: 22017370]
7. Kolch W, Pitt A. Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. *Nat Rev Cancer*. 2010; 10(9):618–629. [PubMed: 20720570]
8. Roepstorff K, et al. Differential effects of EGFR ligands on endocytic sorting of the receptor. *Traffic*. 2009; 10(8):1115–27. [PubMed: 19531065]
9. Raiborg C, Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. *Nature*. 2009; 458(7237):445–52. [PubMed: 19325624]
10. Henne WM, Buchkovich NJ, Emr SD. The ESCRT pathway. *Dev Cell*. 2011; 21(1):77–91. [PubMed: 21763610]
11. Yue X, et al. Mitochondrially localized EGFR is subjected to autophagic regulation and implicated in cell survival. *Autophagy*. 2008; 4:641–649. [PubMed: 18398293]
12. Demory ML, et al. Epidermal Growth Factor Receptor Translocation to the Mitochondria: REGULATION AND EFFECT. *Journal of Biological Chemistry*. 2009; 284(52):36592–36604. [PubMed: 19840943]
13. Yao Y, et al. Mitochondrially localized EGFR is independent of its endocytosis and associates with cell viability. *Acta Biochimica et Biophysica Sinica*. 2010; 42(11):763–770. [PubMed: 20929928]
14. Li C, et al. Nuclear EGFR contributes to acquired resistance to cetuximab. *Oncogene*. 2009; 28(43):3801–3813. [PubMed: 19684613]
15. Wang SC, Hung MC. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. *Clin Cancer Res*. 2009; 15:6484–6489. [PubMed: 19861462]
16. Lo HW. Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. *Discov Med*. 2010; 10:44–51. [PubMed: 20670598]
17. Paez JG, et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. *Science*. 2004; 304(5676):1497–1500. [PubMed: 15118125]
18. Health Quality O. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. *Ontario Health Technology Assessment Series*. 2010; 10(24):1–48.

19. Luca AD, Normanno N. Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer. *Current Drug Targets*. 2010; 11(7):851–864. [PubMed: 20388064]
20. Chung C. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics. *Journal of Oncology Pharmacy Practice*. 2015
21. Ellis PM, et al. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. 2015; 22:2015.
22. Tan X, et al. A Kinase-Independent Role for EGF Receptor in Autophagy Initiation. *Cell*. 2015; 160(1):145–160. [PubMed: 25594178]
23. Lazova R, et al. Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome. *Clinical Cancer Research*. 2012; 18(2):370–379. [PubMed: 22080440]
24. Franovic A, et al. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. *Proceedings of the National Academy of Sciences*. 2007; 104(32):13092–13097.
25. Lum JJ, et al. Growth Factor Regulation of Autophagy and Cell Survival in the Absence of Apoptosis. *Cell*. 2005; 120(2):237–248. [PubMed: 15680329]
26. Lamb CA, Yoshimori T, Tooze SA. The autophagosome: origins unknown, biogenesis complex. *Nat Rev Mol Cell Biol*. 2013; 14(12):759–774. [PubMed: 24201109]
27. Shibutani ST, Yoshimori T. A current perspective of autophagosome biogenesis. *Cell Res*. 2014; 24(1):58–68. [PubMed: 24296784]
28. Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. *Trends in Cell Biology*. 2014; 24(1):26–34. [PubMed: 24295852]
29. Wei Y, et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. *Cell*. 2013; 154(6):1269–84. [PubMed: 24034250]
30. Tan X, et al. LAPT4B is a PtdIns(4,5)P2 effector that regulates EGFR signaling, lysosomal sorting, and degradation. *EMBO J*. 2015; 34(4):475–90. [PubMed: 25588945]
31. Shao G, et al. Molecular cloning and characterization of LAPT4B, a novel gene upregulated in hepatocellular carcinoma. *Oncogene*. 2003; 22:5060–5069. [PubMed: 12902989]
32. Kasper G, et al. The human LAPT4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. *Cancer Letters*. 2005; 224:93–103. [PubMed: 15911104]
33. Tomas A, et al. WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway. *Nat Commun*. 2015:6.
34. Itakura E, et al. Beclin 1 Forms Two Distinct Phosphatidylinositol 3-Kinase Complexes with Mammalian Atg14 and UVRAG. *Molecular Biology of the Cell*. 2008; 19(12):5360–5372. [PubMed: 18843052]
35. Sun Q, et al. Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase. *Proceedings of the National Academy of Sciences*. 2008; 105(49):19211–19216.
36. Matsunaga K, et al. Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. *Nat Cell Biol*. 2009; 11(4):385–96. [PubMed: 19270696]
37. Zhong Y, et al. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. *Nat Cell Biol*. 2009; 11(4):468–76. [PubMed: 19270693]
38. Sun Q, et al. The RUN Domain of Rubicon Is Important for hVps34 Binding, Lipid Kinase Inhibition, and Autophagy Suppression. *Journal of Biological Chemistry*. 2011; 286(1):185–191. [PubMed: 21062745]
39. Bodemann BO, et al. RalB and the exocyst mediate the cellular starvation response by direct activation of autophagosome assembly. *Cell*. 2011; 144(2):253–67. [PubMed: 21241894]

40. Kulich I, et al. Arabidopsis Exocyst Subcomplex Containing Subunit EXO70B1 Is Involved in Autophagy-Related Transport to the Vacuole. *Traffic*. 2013; 14(11):1155–1165. [PubMed: 23944713]
41. Fung C, et al. EGFR tyrosine kinase inhibition induces autophagy in cancer cells. *Cancer Biol Ther*. 2012; 13(14):1417–24. [PubMed: 22954701]
42. Han W, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. *PLoS One*. 2011; 6(6):e18691. [PubMed: 21655094]
43. Li YY, et al. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. *Lung Cancer*. 2013; 81(3):354–61. [PubMed: 23769318]
44. Choi HS, et al. Autophagy Inhibition with Monensin Enhances Cell Cycle Arrest and Apoptosis Induced by mTOR or Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cells. *Tuberc Respir Dis (Seoul)*. 2013; 75(1):9–17. [PubMed: 23946753]
45. Eimer S, et al. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. *Cancer Biol Ther*. 2011; 11(12):1017–27. [PubMed: 21508666]
46. Sobhakumari A, et al. NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. *Toxicol Appl Pharmacol*. 2013; 272(3):736–45. [PubMed: 23917044]
47. Zou Y, et al. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib. *J Thorac Oncol*. 2013; 8(6):693–702. [PubMed: 23575415]
48. Dragowska WH, et al. Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. *PLoS One*. 2013; 8(10):e76503. [PubMed: 24146879]
49. Sakuma Y, et al. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells. *Lab Invest*. 2013; 93(10):1137–46. [PubMed: 23938604]
50. Oksvold MP, et al. UV induces tyrosine kinase-independent internalisation and endosome arrest of the EGF receptor. *Journal of Cell Science*. 2002; 115(4):793–803. [PubMed: 11865035]
51. Oksvold MP, et al. UV-Radiation-Induced Internalization of the Epidermal Growth Factor Receptor Requires Distinct Serine and Tyrosine Residues in the Cytoplasmic Carboxy-Terminal Domain. *Radiation Research*. 2004; 161(6):685–691. [PubMed: 15161351]
52. Vergarauregui S, Miguel AS, Puertollano R. Activation of p38 Mitogen-Activated Protein Kinase Promotes Epidermal Growth Factor Receptor Internalization. *Traffic*. 2006; 7(6):686–698. [PubMed: 16683917]
53. Zwang Y, Yarden Y. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. *The EMBO Journal*. 2006; 25(18):4195–4206. [PubMed: 16932740]
54. Orcutt KP, et al. Erlotinib-Mediated Inhibition of EGFR Signaling Induces Metabolic Oxidative Stress through NOX4. *Cancer Research*. 2011; 71(11):3932–3940. [PubMed: 21482679]
55. Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. *Cell Death & Differentiation*. 2015; 22(3):377–388. [PubMed: 25257172]
56. Tong J, Taylor P, Moran MF. Proteomic Analysis of the Epidermal Growth Factor Receptor (EGFR) Interactome and Post-translational Modifications Associated with Receptor Endocytosis in Response to EGF and Stress. *Molecular & Cellular Proteomics*. 2014; 13(7):1644–1658. [PubMed: 24797263]
57. Tong J, et al. Epidermal Growth Factor Receptor Phosphorylation Sites Ser991 and Tyr998 Are Implicated in the Regulation of Receptor Endocytosis and Phosphorylations at Ser1039 and Thr1041. *Molecular & Cellular Proteomics*. 2009; 8(9):2131–2144. [PubMed: 19531499]
58. He Y-Y, et al. Epidermal Growth Factor Receptor Down-regulation Induced by UVA in Human Keratinocytes Does Not Require the Receptor Kinase Activity. *Journal of Biological Chemistry*. 2003; 278(43):42457–42465. [PubMed: 12930839]
59. Wang J, Wu GS. Role of autophagy in cisplatin resistance in ovarian cancer cells. *Journal of Biological Chemistry*. 2014; 289(24):17163–17173. [PubMed: 24794870]
60. Harhaji-Trajkovic L, et al. AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. *Journal of cellular and molecular medicine*. 2009; 13(9b):3644–3654. [PubMed: 20196784]

61. Liu D, et al. Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells. *Medical oncology*. 2011; 28(1):105–111. [PubMed: 20041317]
62. Garcia-Cano J, et al. Exploiting the potential of autophagy in cisplatin therapy: a new strategy to overcome resistance. *Oncotarget*. 2015;5. [PubMed: 25575820]
63. Bao L, et al. Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells. *Molecular medicine reports*. 2015; 11(1):91–98. [PubMed: 25322694]
64. Misovic M, et al. Short-term exposure to UV-A, UV-B, and UV-C irradiation induces alteration in cytoskeleton and autophagy in human keratinocytes. *Ultrastructural pathology*. 2013; 37(4):241–248. [PubMed: 23758094]
65. Chen L-H, et al. Targeting protective autophagy exacerbates UV-triggered apoptotic cell death. *International journal of molecular sciences*. 2012; 13(1):1209–1224. [PubMed: 22312313]
66. Zhao Y, et al. Autophagy is induced by UVA and promotes removal of oxidized phospholipids and protein aggregates in epidermal keratinocytes. *Journal of Investigative Dermatology*. 2013; 133(6):1629–1637. [PubMed: 23340736]
67. Shen J, et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. *Nature*. 2013; 497(7449):383–387. [PubMed: 23636329]
68. Mishra OP, Delivoria-Papadopoulos M. Effect of Hypoxia on Activation of Epidermal Growth Factor Receptor (EGFR) Kinase and Src Kinase in the Cerebral Cortex of Newborn Piglets. *The FASEB Journal*. 2006; 20(5):LB115.
69. Fang Y, Tan J, Zhang Q. Signaling pathways and mechanisms of hypoxia-induced autophagy in the animal cells. *Cell biology international*. 2015
70. Ravid T, et al. Epidermal Growth Factor Receptor Activation under Oxidative Stress Fails to Promote c-Cbl Mediated Down-regulation. *Journal of Biological Chemistry*. 2002; 277(34):31214–31219. [PubMed: 12063263]
71. Filosto S, et al. EGF Receptor Exposed to Oxidative Stress Acquires Abnormal Phosphorylation and Aberrant Activated Conformation That Impairs Canonical Dimerization. *PLoS One*. 2011; 6(8):e23240. [PubMed: 21853092]
72. Lee S-R, et al. Reversible Inactivation of Protein-tyrosine Phosphatase 1B in A431 Cells Stimulated with Epidermal Growth Factor. *Journal of Biological Chemistry*. 1998; 273(25):15366–15372. [PubMed: 9624118]
73. Denu JM, Tanner KG. Specific and Reversible Inactivation of Protein Tyrosine Phosphatases by Hydrogen Peroxide: Evidence for a Sulfenic Acid Intermediate and Implications for Redox Regulation. *Biochemistry*. 1998; 37(16):5633–5642. [PubMed: 9548949]
74. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. *Nat Rev Mol Cell Biol*. 2011; 12(2):104–117. [PubMed: 21252999]
75. Khan EM, et al. Epidermal Growth Factor Receptor Exposed to Oxidative Stress Undergoes Src- and Caveolin-1-dependent Perinuclear Trafficking. *Journal of Biological Chemistry*. 2006; 281(20):14486–14493. [PubMed: 16407214]
76. Norambuena, As, et al. Phosphatidic Acid Induces Ligand-independent Epidermal Growth Factor Receptor Endocytic Traffic through PDE4 Activation. *Molecular Biology of the Cell*. 2010; 21(16):2916–2929. [PubMed: 20554760]
77. Salazar G, Gonzalez A. Novel Mechanism for Regulation of Epidermal Growth Factor Receptor Endocytosis Revealed by Protein Kinase A Inhibition. *Molecular Biology of the Cell*. 2002; 13(5):1677–1693. [PubMed: 12006662]
78. Stephan JS, et al. The Tor and PKA signaling pathways independently target the Atg1/Atg13 protein kinase complex to control autophagy. *Proceedings of the National Academy of Sciences*. 2009; 106(40):17049–17054.
79. Torres-Quiroz F, Filteau M, Landry CR. Feedback regulation between autophagy and PKA. *Autophagy*. 2015
80. Filteau M, et al. Systematic identification of signal integration by protein kinase A. *Proceedings of the National Academy of Sciences*. 2015; 112(14):4501–4506.

81. Dittmann K, et al. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. *Molecular Cancer*. 2008; 7(1):69. [PubMed: 18789131]
82. Liao H-J, Carpenter G. Cetuximab/C225-Induced Intracellular Trafficking of Epidermal Growth Factor Receptor. *Cancer Research*. 2009; 69(15):6179–6183. [PubMed: 19602593]
83. Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. *Cancer Biology & Therapy*. 2011; 11(9):777–792. [PubMed: 21293176]
84. Li X, et al. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. *Autophagy*. 2010; 6(8):1066–77. [PubMed: 20864811]
85. Li X, Fan Z. The Epidermal Growth Factor Receptor Antibody Cetuximab Induces Autophagy in Cancer Cells by Downregulating HIF-1 α and Bcl-2 and Activating the Beclin 1/hVps34 Complex. *Cancer Research*. 2010; 70(14):5942–5952. [PubMed: 20634405]
86. Schmidt-Ullrich RK, et al. Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. *International journal of radiation oncology, biology, physics*. 1994; 29(4):813–819.
87. Wanner G, et al. Activation of protein kinase C α stimulates DNA-repair via epidermal growth factor receptor nuclear accumulation. *Radiotherapy and Oncology*. 2008; 86(3):383–390. [PubMed: 18037521]
88. Bao J, et al. Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome. *Journal of Biological Chemistry*. 2000; 275(34):26178–26186. [PubMed: 10816576]
89. Xu Y, et al. Ultraviolet irradiation-induces epidermal growth factor receptor (EGFR) nuclear translocation in human keratinocytes. *Journal of cellular biochemistry*. 2009; 107(5):873–880. [PubMed: 19415674]
90. Nijkamp MM, et al. Interaction of EGFR with the tumour microenvironment: implications for radiation treatment. *Radiotherapy and Oncology*. 2013; 108(1):17–23. [PubMed: 23746695]
91. Chaachouay H, et al. Autophagy contributes to resistance of tumor cells to ionizing radiation. *Radiotherapy and Oncology*. 2011; 99(3):287–292. [PubMed: 21722986]
92. Koukourakis MI, et al. Intensified autophagy compromises the efficacy of radiotherapy against prostate cancer. *Biochemical and biophysical research communications*. 2015; 461(2):268–274. [PubMed: 25887800]
93. Zhu H, et al. EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocation of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. *Cancer Lett*. 2010; 294:101–110. [PubMed: 20153921]
94. Che TF, et al. Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC. *Oncotarget*. 2015; 6(35):37349–66. [PubMed: 26497368]
95. Bollu LR, et al. Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells. *Cell Cycle*. 2014; 13(15):2415–30. [PubMed: 25483192]
96. Cao X, et al. EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocation: A potential mechanism of EGFR-driven antagonism of apoptosis. *Molecular Cancer*. 2011; 10(1):26. [PubMed: 21388543]
97. Dreier A, et al. Cetuximab induces mitochondrial translocation of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance? *Tumor Biology*. 2012; 33(1):85–94. [PubMed: 21986964]
98. Jutten B, et al. EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival. *Radiother Oncol*. 2013; 108(3):479–83. [PubMed: 23891088]
99. Jutten B, Rouschop KM. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. *Cell Cycle*. 2014; 13(1):42–51. [PubMed: 24335351]
100. Shaughnessy R, et al. Epidermal growth factor receptor endocytic traffic perturbation by phosphatidate phosphohydrolase inhibition: new strategy against cancer. *FEBS Journal*. 2014; 281(9):2172–2189. [PubMed: 24597955]
101. Karnthaler-Benbakka C, et al. Tumor-Targeting of EGFR Inhibitors by Hypoxia-Mediated Activation. *Angewandte Chemie International Edition*. 2014; 53(47):12930–12935.

102. Henriksen L, et al. Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands. *PloS one*. 2013; 8(3)
103. Lin SY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. *Nat Cell Biol*. 2001; 3:802–808. [PubMed: 11533659]
104. Shaughnessy R, et al. Epidermal growth factor receptor endocytic traffic perturbation by phosphatidate phosphohydrolase inhibition: new strategy against cancer. *FEBS Journal*. 2014; 281(9):2172–2189. [PubMed: 24597955]
105. Choi EJ, et al. Targeting Epidermal Growth Factor Receptor-Associated Signaling Pathways in Non-Small Cell Lung Cancer Cells: Implication in Radiation Response. *Molecular Cancer Research*. 2010; 8(7):1027–1036. [PubMed: 20587532]
106. Sartor CI. Epidermal growth factor family receptors and inhibitors: radiation response modulators. *Seminars in radiation oncology*. 2003; 13(1):22–30. [PubMed: 12520461]
107. Miettinen PJ, et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. *Nature*. 1995; 376(6538):337–41. [PubMed: 7630400]
108. Threadgill DW, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. *Science*. 1995; 269(5221):230–4. [PubMed: 7618084]
109. Sibilio M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. *Science*. 1995; 269(5221):234–8. [PubMed: 7618085]
110. Luetke NC, et al. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. *Genes & Development*. 1994; 8(4):399–413. [PubMed: 8125255]
111. Kancha RK, et al. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. *Clinical Cancer Research*. 2009; 15(2):460–467. [PubMed: 19147750]
112. Weihua Z, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. *Cancer Cell*. 2008; 13(5):385–93. [PubMed: 18455122]
113. Coker KJ, Staros JV, Guyer CA. A kinase-negative epidermal growth factor receptor that retains the capacity to stimulate DNA synthesis. *Proc Natl Acad Sci U S A*. 1994; 91(15):6967–71. [PubMed: 8041731]
114. Ewald JA, et al. Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells. *Exp Cell Res*. 2003; 282(2):121–31. [PubMed: 12531698]
115. Eldredge ER, et al. Activation of c-fos gene expression by a kinase-deficient epidermal growth factor receptor. *Molecular and cellular biology*. 1994; 14(11):7527–7534. [PubMed: 7935468]
116. Hanabata Y, et al. Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma. *Odontology*. 2012; 100(2):156–163. [PubMed: 21607591]
117. Hamasaki M, et al. Autophagosomes form at ER-mitochondria contact sites. *Nature*. 2013; 495(7441):389–93. [PubMed: 23455425]
118. Fader CM, Colombo MI. Autophagy and multivesicular bodies: two closely related partners. *Cell Death Differ*. 2008; 16(1):70–78. [PubMed: 19008921]
119. Eden ER, et al. Membrane contacts between endosomes and ER provide sites for PTP1B-epidermal growth factor receptor interaction. *Nat Cell Biol*. 2010; 12(3):267–72. [PubMed: 20118922]
120. Friedman JR, et al. Endoplasmic reticulum-endosome contact increases as endosomes traffic and mature. *Mol Biol Cell*. 2013; 24(7):1030–40. [PubMed: 23389631]
121. Raiborg C, et al. Repeated ER-endosome contacts promote endosome translocation and neurite outgrowth. *Nature*. 2015; 520(7546):234–238. [PubMed: 25855459]
122. Raiborg C, Wenzel EM, Stenmark H. ER-endosome contact sites: molecular compositions and functions. *The EMBO Journal*. 2015

Trends

EGFR is overexpressed and/or hyperactivated in most epithelial cancers, but EGFR targeting therapies have had limited clinical benefit.

Many intrinsic and iatrogenic cellular stresses stimulate ligand-independent EGFR internalization and signaling that provide a survival advantage to tumor cells.

Cellular stresses stimulate EGFR internalization and intracellular accumulation with a consequent induction of autophagic responses.

Overcoming therapeutic resistance resulting from ligand-independent EGFR functions promises new treatment strategies for EGFR-overexpressing cancers.

Figure 1. EGF- and stress-induced EGFR trafficking

Ligand and various cellular stresses or stress inducers stimulate EGFR internalization and intracellular trafficking. Following EGF treatment or stress stimulation, EGFR is internalized and it then can be recycled back to the plasma membrane or sorted to multivesicular endosomes (MVEs), mitochondria, ER and nuclei. Different background colors highlight EGFR trafficking to specific subcellular destinations (red compartments) upon different cellular stresses at the top. At each location, stress-stimulated EGFR have both kinase-dependent and independent functions. Ligand- or stress-activated EGFR signals from various compartments unless it is sequestered on intraluminal vesicles (ILVs) in the lumen of MVEs or delivered to the lysosome for degradation. While ligand-stimulated

EGFR trafficking to MVEs targets the receptor for lysosomal degradation, most stresses cause perinuclear arrest of EGFR at non-degradative MVEs, where EGFR has been shown to undergo intraluminal sorting and back-fusion recycling in response to UV irradiation.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 2. Stress-induced EGFR endosomal arrest and autophagy induction

Most cellular stress stimuli cause EGFR arrest at non-degradative endosomes where the receptors have both kinase signaling and kinase-independent functions, although many stressors also trigger EGFR trafficking to other subcellular locations. Serum starvation and EGFR tyrosine kinase inhibitors – erlotinib and gefitinib – have been recently shown to trigger a kinase-independent role for EGFR at endosomes in autophagy initiation. Such a role for EGFR might also be triggered by most other stress stimuli shown in the figure, as they also induce both EGFR endosomal arrest and autophagy upregulation. The inactive EGFR is arrested at endosomes upon serum starvation via a protein-protein interaction with an endosomal protein LAPT4B or by erlotinib and gefitinib through unknown mechanisms. Exocyst is then recruited and facilitates EGFR-mediated Rubicon disassociation from the Beclin 1 complex, which releases Beclin 1 from Rubicon inhibition and activates autophagy initiation.

Figure 3. Therapeutic strategies to be combined with canonical treatments for EGFR-overexpressing cancers

Given the substantial roles for stress-induced EGFR trafficking and signaling in cancer cells, more therapeutic strategies need to be considered in addition to canonical treatments such as radiotherapy and EGFR-targeting chemotherapy. Major strategies include inhibiting the kinase independent role of EGFR in autophagy, blocking transactivated EGFR signaling from various compartments, interfering with stress-induced EGFR trafficking or alternatively directing the receptor for lysosomal degradation. PKA inhibition – though it mimics stress-induced EGFR trafficking – can be explored as a supplementary therapeutic strategy as it has been found with anti-tumor activities. Additionally, the features of EGFR-overexpressing tumor cells – hypoxia and oxidative stress, etc. – might allow the engineering of EGFR inhibitors for precise delivery to these cells.

Table 1

Overview of stress-induced EGFR trafficking pathways.

Stress type	Ub of EGFR	EGFR degradation	Endocytosis	Intracellular trafficking	Autophagy induction	References
TGF α	Yes	No	Mainly clathrin-mediated	Rapid recycling	No	[8, 102]
EGF	Yes	Yes	Mainly clathrin-mediated	Partially recycled; mostly degraded in the lysosome; mitochondrial and nuclear translocation	No	[6, 8, 12, 81, 102, 103]
UV	No	No	p38MAPK- and clathrin-mediated	Endosomal arrest; Nuclear translocation	Yes	[33, 50–53, 58, 64–66, 89]
Cisplatin	No	No	p38MAPK- and clathrin-mediated	Endosomal arrest	Yes	[33, 53, 59–63]
Anisomycin	No	Yes	p38MAPK- and clathrin-mediated	Rapid degradation; Mitochondrial translocation	Yes	[52, 56, 57, 96]
TNF- α	No	No	p38MAPK- and clathrin-mediated	Rapid recycling	Yes	[53]
Serum starvation	?	No	Clathrin-mediated basal endocytosis?	Endosomal arrest	Yes	[22, 29]
Erlotinib Gefitinib	?	No	Caveolin-mediated?	Endosomal arrest; Mitochondria; promotes cetuximab-induced nuclear translocation	Yes	[22, 42, 43, 45–49, 96]
Hypoxia	?	No	Src- and caveolin- mediated?	Endosomal arrest	Yes	[67–69]
Oxidative stress	No	No	Src- and caveolin- mediated	Endosomal arrest; Nuclear translocation	Yes	[46, 54, 55, 70, 71, 75, 89]
PKA inhibition	No	No	Clathrin-dependent and -independent	Endosomal arrest	Yes	[76–80, 104]
Cetuximab	?	Yes	Src- and caveolin- mediated	Endosomal arrest? Mitochondria translocation of EGFRvIII; ER and Nuclear translocation of EGFR	Yes	[2, 14, 82–85, 97]
Ionizing irradiation	No	No	Src- and caveolin- mediated	Endosomal arrest? Nuclear translocation	Yes	[51, 81, 86–88, 90, 91, 105, 106]